

Codexis Pipeline Snapshot



Pipeline Project Category	Pre-Commercial		Commercial
	Codexis Driven	CodeEvolver® Licensee Driven	Codexis Driven
Biocatalysts for Partners to Reduce Small Molecule Costs:			
<i>Clinical Phase II / III</i>	7	1	n.a.
<i>Patented Drugs</i>	1	2	2
<i>Generic Drugs</i>	2		5
Partnered Projects for Other Value Creation Opportunities:			
<i>To Discover & Develop Novel Biologic Drugs</i>	2		
<i>To Improve Products & Processes In Other Industries</i>	2		1
Self-Funded Projects	4	n.a.	
Pipeline Total as of June 30, 2016	18	3	8

For a project or product to register, it must have generated > \$100,000 in revenue or incurred > \$100,000 in costs over the prior 2 years.

A project or product is Pre-Commercial if it is still being developed by Codexis and/or has yet to be commercialized by the customer.

Guide to Codexis Pipeline Snapshot



Slide covers two-year period from the third quarter of 2014 through the second quarter of 2016

Row Headers

- > Categories in which CodeEvolver® protein engineering can add value to customers and markets
- > Excludes pharmaceutical projects prior to and through Phase 1 development, which contribute minimal revenues

Column Headers

- > **Pre-Commercial Codexis Driven** projects related to products that have yet to be commercially launched by Codexis customers
- > **Pre-Commercial CodeEvolver® Licensee Driven** are biocatalysts development by licensing partners through their in-house R&D with the CodeEvolver® protein engineering platform technology
- > **Commercial** projects or products are fully commercialized by both Codexis and customers and are sources of sustained revenue for Codexis